Novel polymorph of cabozantinib hemifumarate sesquihydrate (form a), cabozantinib hemifumarate hemipentahydrate (form b) and method of preparation
Novel polymorphic forms of cabozantinib hemifumarate sesquihydrate and hemipentahydrate are developed, addressing the need for improved stability and purity, ensuring high yield and stability under accelerated conditions, thus enhancing pharmaceutical formulations.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- DEVA HLDG
- Filing Date
- 2024-12-25
- Publication Date
- 2026-07-02
AI Technical Summary
There is a need for new salts and polymorphic forms of cabozantinib with improved physical and chemical properties to enhance the characteristics of pharmaceutical formulations, particularly in terms of stability, solubility, dissolution rate, and bioavailability.
The development of novel polymorphic forms of cabozantinib hemifumarate sesquihydrate (Form A) and hemipentahydrate (Form B) with high purity and stability, achieved through a preparation process involving the addition of fumaric acid and subsequent stirring and solvent washing, ensuring high yield and purity greater than 99.95%.
The new polymorphic forms exhibit excellent crystalline stability under accelerated conditions, maintaining their form without polymorphic transformation or degradation, thereby enhancing the stability and quality of pharmaceutical compositions.
Smart Images
Figure IMGF000001_0001 
Figure IMGF000002_0001 
Figure IMGF000002_0002
Abstract
Description
[0001] DESCRIPTION
[0002] NOVEL POLYMORPH OF CABOZANTINIB HEMIFUMARATE SESQUIHYDRATE
[0003] (FORM A), CABOZANTINIB HEMIFUMARATE HEMIPENTAHYDRATE (FORM B)
[0004] AND METHOD OF PREPARATION
[0005] Technical Field
[0006] The present invention refers to a novel crystalline polymorphic form of cabozantinib hemifumarate sesquihydrate designated as Form A, a novel crystalline polymorphic form of cabozantinib hemifumarate hemipentahydrate designated as Form B and a process for its preparation.
[0007] The invention further relates to pharmaceutical compositions containing Form A, Form B and their use for the treatment of cancer.
[0008] Background Art
[0009] Cabozantinib is chemically known as A-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-M-(4-fluorophenyl)cyclopropane- 1,1 -dicarboxamide (CAS No: 849217-68-1) and represented by the following structural formula:
[0010]
[0011] Cabozantinib
[0012] Cabozantinib is marketed in the United States under the trade name COMETRIQ® and CABOMETYX® by Exelixis Inc. COMETRIQ® is indicated for use in the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC) and CABOMETYX® is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy.
[0013] CABOMETYX (Cabozantinib) tablets are supplied as film-coated tablets containing 20 mg, 40 mg, or 60 mg of cabozantinib, which is equivalent to 25 mg, 51 mg, or 76 mg of cabozantinib (S)-malate, respectively.
[0014] International (PCT) publication No. WO 2005030140 Al first disclosed cabozantinib. Further the application discloses processes for the preparation of cabozantinib, pharmaceutical preparation of cabozantinib and therapeutic application thereof.International (PCT) publication No. WO 2010083414 Al, discloses (L)-malate salt of cabozantinib and further claims said salt is in the crystalline forms (N-l), (N-2) and amorphous and a processes of preparation thereof.
[0015] In 2012, the U.S. FDA approved the company's cabozantinib malate (1:1), under the trade name COMETRIQ.
[0016] Several salts of cabozantinib including various crystalline forms are disclosed.
[0017] International (PCT) publication No. WO 2016150966 Al discloses crystalline cabozantinib hydrochloride as well as crystalline cabozantinib phosphate and process for its preparation.
[0018] U.S. Patent No. 9,815,789 B2, discloses crystalline forms Ml, M2, M3 & M4 of (L)-malate salt of cabozantinib and processes of preparation thereof.
[0019] CN104961681 A discloses various acid addition salts of cabozantinib and process for its preparation. CN104961680 A discloses crystal A and crystal B of hydrochloride salt of cabozantinib and process for its preparation.
[0020] PCT publication WO 2020057622 Al, discloses crystalline forms CSI and CSIII of cabozantinib-(S)-malate salt.
[0021] The structure of cabozantinib hemifumarate sesquihydrate and cabozantinib hemifumarate hemipentahydrate corresponds to the following formula:
[0022]
[0023] Cabozantinib hemifumarate sesquihydrate
[0024]
[0025] Cabozantinib hemifumarate hemipentahydrate
[0026] Different salts and solid state forms of an active pharmaceutical ingredient may possess different properties.The discovery of a new salt of an active substance provides an opportunity to improve its characteristics, increasing the possibilities available to a formulation specialist when developing a new pharmaceutical form, a drug with a particular release profile or a specific dissolution degree. Based on these considerations, there still appears a need for new salts of cabozantinib having further improved physical and / or chemical properties. Hence it was thought worthwhile by the inventors of the present application to explore pharmaceutically novel salts of cabozantinib with good chemical purity and improved stability characteristics, which may further improve the characteristics of cabozantinib in finished medicinal product.
[0027] Summary of the invention
[0028] The object of the present invention is to provide a new polymorphic form of cabozantinib hemifumarate sesquihydrate and a new polymorphic form of cabozantinib hemifumarate hemipentahydrate .
[0029] Another object of the present invention is to provide pharmaceutical compositions comprising new polymorphic form of cabozantinib hemifumarate sesquihydrate and new polymorphic form of cabozantinib hemifumarate hemipentahydrate.
[0030] Technical Problem
[0031] Active pharmaceutical ingredients are individual components that are used as a part of a finished pharmaceutical drug or medicinal product, where they provide the pharmacological activity.
[0032] Research and development projects in the pharmaceutical industry mainly aim to investigate different possible salts, polymorphs and processes to produce active pharmaceutical ingredients.
[0033] Salt formation in general is vitally important in drug substance synthesis as well as overall pharmaceutical development and manufacture.
[0034] Salt forms of drug substances have significant effects on physicochemical properties of the drug influencing its quality, safety, and performance.
[0035] Polymorphism, the occurrence of different crystal forms, is a property of some molecules and molecular complexes. A single molecule, may give rise to a variety of crystalline forms having distinct crystal structures and physical properties like melting point, thermal behaviours, X-ray powder diffraction (XRPD) pattern, Infrared absorption fingerprint, Raman absorption fingerprint, and solid state (13C) NMR spectrum. One or more of these tecniques may be used to distinguish different polymorphic forms of a compound. Difference in the physical properties of different crystalline forms results from the orientation and intermolecular interactions of adjacent molecules or complexes in the bulk solid.
[0036] The relationship between polymorphic forms of pharmaceutically active ingredient andpharmaceutical product is well known in the pharmaceutical industry. Pharmaceutical formulation is affected by polymorphic form of the pharmaceutically active ingredient.
[0037] Discovery of new salts and polymorphic forms of an active pharmaceutical ingredient provides a new opportunity to improve solubility, dissolution rate, drug absorption and bioavailability of pharmaceutical finished product, therefore, development of new salts and polymorphic forms are always encouraged.
[0038] According to the need, studies have been done to develop novel polymorph of cabozantinib hemifumarate sesquihydrate and novel polymorph of cabozantinib hemifumarate hemipentahydrate having advantageous properties which are useful and suitable for the preparation of various pharmaceutical compositions.
[0039] Solution to Problem
[0040] The present disclosure includes a novel polymorph of cabozantinib hemifumarate sesquihydrate and novel polymorph of cabozantinib hemifumarate hemipentahydrate. The new polymorph of cabozantinib hemifumarate sesquihydrate and new polymorph of cabozantinib hemifumarate hemipentahydrate, besides being stable, meets the pharmaceutical requirements such as storage, shelf life and high purity.
[0041] Description of embodiments
[0042] The first aspect of the present invention is to provide a novel crystalline form of cabozantinib hemifumarate sesquihydrate, a novel crystalline form of cabozantinib hemifumarate hemipentahydrate and their processes for the preparation thereof. The crystalline form of cabozantinib hemifumarate sesquihydrate hereinafter designated as “Form A”. The crystalline form of cabozantinib hemifumarate hemipentahydrate hereinafter designated as “Form B”.
[0043] Characteristic 2-theta values of cabozantinib hemifumarate sesquihydrate (Form A) and cabozantinib hemifumarate hemipentahydrate (Form B).
[0044] Table 1. Characteristic 2-theta values of cabozantinib hemifumarate sesquihydrate (Form A) and cabozantinib hemifumarate hemipentahydrate (Form B)
[0045]
[0046]
[0047] A second aspect of the present invention relates to a process for preparing cabozantinib hemifumarate sesquihydrate (Form A) and cabozantinib hemifumarate hemipentahydrate (Form B).
[0048] Described is a process for the preparation of crystalline cabozantinib hemifumarate sesquihydrate (Form A) and crystalline cabozantinib hemifumarate hemipentahydrate (Form B) which comprises: a) adding fumaric acid and / or its solution into the cabozantinib mixture at step (a),
[0049] b) stirring the reaction solution at step (b) at a suitable temperature,
[0050] c) filtering to isolate the obtained solid,
[0051] d) washing the obtained solid as pure crystalline cabozantinib hemifumarate sesquihydrate (Form A) or crystalline cabozantinib hemifumarate hemipentahydrate (Form B) with a suitable solvent.
[0052] Wherein suitable solvent in step (a), step (b) and step (e) is selected from, water, methanol, ethanol, 2-propanol, 1 -propanol, 1 -butanol, 2-butanol, tert-butyl alcohol, 1 -pentanol and 2-pentanol or mixtures thereof.
[0053] The suitable temperature used in step (c) is selected from 20 °C to 60 °C.
[0054] The degree of purity of the active ingredient and the resulting possible changes of the efficacy, furtherimportant properties for the pharmaceutical processing can be affected in an adverse manner.
[0055] The process of the present invention affords crystalline Form A and crystalline Form B in high purity and high yield. The crystalline Form A and Form B are obtained having purity greater than 99.95% by area percentage in ultra-performance liquid chromatography (UPLC).
[0056] Stability plays an important role in the drug development process. Stability of a pharmaceutical product may be defined as the capability of that particular formulation, in a specific container or closure system, to remain within its chemical, physical, microbiological, therapeutic and toxicological specifications to assure its attributed quality, e.g., identity, purity, strength etc. until drug expiry.
[0057] Stability of a pharmaceutical product is strongly influenced by changes in solid-state form of the drug substance. The changes in solid state form of the drug substance may be resulted from the conditions of manufacturing process. Examples of processing that may cause polymorphic changes including grinding, milling, heating, and applying compression. Manufacturing conditions that include a solvent (e.g., wet granulation, polymorphs in solution, and polymorphs in suspension) may facilitate changes in the solid-state form of drug substance. These variations comprising polymorphic transformations, hydrate / solvate formations and dehydration / desolvation reactions in the solid-state form of the drug substance, may cause stability problems in finished pharmaceutical products. Therefore, crystalline stability of the drug substance has a critical role on satisfying the essentialities of qualified pharmaceutical product and stable polymorphs of drug substance should be used in pharmaceutical formulations.
[0058] For a third aspect of the present invention, crystalline stability of cabozantinib hemifumarate sesquihydrate (Form A) and crystalline stability of cabozantinib hemifumarate hemipentahydrate (Form B) of the present disclosure was investigated under the following conditions: a sample was kept in an open flask at 105 °C for 10 days. The crystalline stability referred here, is the stability of a polymorphic form of drug substance with respect to polymorph transformations, hydration, dehydration, or amorphization through time under these conditions.
[0059] The crystalline stability of cabozantinib hemifumarate sesquihydrate (Form A) and crystalline stability of cabozantinib hemifumarate hemipentahydrate (Form B) were investigated and determined by X-ray powder diffraction and differential scanning calorimetry methods. Results showed that any polymorphic transformation to another crystal form or any degradation in crystalline cabozantinib hemifumarate sesquihydrate (Form A) and crystalline cabozantinib hemifumarate hemipentahydrate (Form B) did not occur. Cabozantinib hemifumarate sesquihydrate (Form A) and cabozantinib hemifumarate hemipentahydrate (Form B) showed crystalline stability under dry heating at 105 °C for 10 days.The chemical stability of crystalline cabozantinib hemifumarate sesquihydrate (Form A) and the chemical stability of crystalline cabozantinib hemifumarate hemipentahydrate (Form B) are also important and their stability in finished product at room temperature storage can be predicted from short-term storage under accelerated conditions at high temperature and humidity. The results indicate that crystalline cabozantinib hemifumarate sesquihydrate (Form A) and crystalline cabozantinib hemifumarate hemipentahydrate (Form B) has good stability.
[0060] Brief description of the drawings:
[0061] Figure 1 shows the X-ray powder diffraction (XRPD) pattern of crystalline cabozantinib hemifumarate sesquihydrate Form A
[0062] Figure 2 shows the1H NMR spectrum of cabozantinib hemifumarate sesquihydrate Form A Figure 3 shows the13C NMR spectrum of cabozantinib hemifumarate sesquihydrate Form A Figure 4 shows the Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) spectrum of cabozantinib hemifumarate sesquihydrate Form A
[0063] Figure 5 shows the X-ray powder diffraction (XRPD) pattern of crystalline cabozantinib hemifumarate hemipentahydrate Form B
[0064] Figure 6 shows the
[0065]
[0066] NMR spectrum of cabozantinib hemifumarate hemipentahydrate Form B Figure 7 shows the Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) spectrum of cabozantinib hemifumarate hemipentahydrate Form B
[0067] Instrumental parameters:
[0068] NMR:
[0069] NMR, and13C NMR analyses were performed on a 400 MHz NMR spectrometer (JEOL Ltd., Tokyo, Japan) using deuterated dimethyl sulfoxide (DMSO-tfo) as a solvent.
[0070] FTIR:
[0071] Samples were measured as neat by ATR (attenuated total reflectance) on Shimadzu FTIR Spectrometer IR Spirit (Shimadzu Corporation, Kyoto, Japan) in the range of 400 - 4000 cm-1with 20 scans and 2 cm-1resolution.
[0072] PXRD:
[0073] X-Ray powder diffractograms were measured using a Shimadzu Lab-X XRD-6100 X-ray diffractometer (Shimadzu Corporation, Japan) by using following instrument parameters:
[0074] The measurement conditions were as follows:
[0075] Radiation: Cu (1.5406 A)
[0076] Filter for KP: NickelVoltage: 40.0 kV
[0077] Current: 30.0 mA
[0078] Auto slit: not used
[0079] Divergence slit: 1.0°
[0080] Scatter slit: 1.0°
[0081] Receiving slit: 0.30 mm with a Graphite monochromatic
[0082] Drive axis: Theta-2Theta
[0083] Scan range: 3.00 -40.00°
[0084] Scan mode: continuous scan
[0085] Scan speed: 1.07min
[0086] Sampling pitch: 0.02°
[0087] Following examples are provided to enable one skilled in the art to practice the invention and are merely illustrative of the invention. The examples should not be read as limiting the scope of the invention.
[0088] EXAMPLE-1
[0089] Preparation of cabozantinib hemifumarate sesquihydrate Form A
[0090] A reactor was charged with cabozantinib (2 g, 3.98 mmol, 1.0 equiv.) and fumaric acid (0.51 g, 4.39 mmol, 1.1 equiv.) were added into a tetrahydrofuran / water (15 mL / 1.5 mL) and stirred at 60 - 65 °C for 1 - 2 h. After completion of the reaction, the mixture was filtered and product crystals were washed with water to afford white to off-white cabozantinib hemifumarate sesquihydrate crystal Form A (yield: 65%, KF: 4.93%).
[0091] EXAMPLE-2
[0092] Preparation of cabozantinib hemifumarate hemipentahydrate (Form B)
[0093] A reactor was charged with cabozantinib (10 g, 19.94 mmol, 1.0 equiv.) and fumaric acid (2.54 g, 21.88 mmol, 1.1 equiv.) were added into a tetrahydrofuran / water (100 mL / 410 mL) and stirred at 60 - 65 °C for 1 - 2 h. After completion of the reaction, the mixture was filtered and product crystals were washed with water to afford white to off-white cabozantinib hemifumarate hemipentahydrate crystal Form B (yield: 96%, KF: 7.25%).
Claims
CLAIMS1. A crystalline Form A of cabozantinib hemifumarate sesquihydrate and a crystalline Form B of Cabozantinib hemifumarate hemipentahydrate wherein the X-ray powder diffraction patterns are as defined by the following table:
2. The crystalline Form A of cabozantinib hemifumarate sesquihydrate according to claim 1, wherein the X-ray powder diffraction pattern is as shown in Figure 1.
3. The crystalline Form B of cabozantinib hemifumarate hemipentahydrate according to claim 1, wherein the X-ray powder diffraction pattern is as shown in Figure 5.
4. A process for the synthesis of crystalline Form A of cabozantinib hemifumarate sesquihydrate according to claim 1 or 2 and crystalline Form B of cabozantinib hemifumarate hemipentahydrate according to claim 1 or 3, comprising:a) dissolving and / or suspending cabozantinib in a suitable solvent and / or solvent mixture, b) adding fumaric acid and / or its solution into the cabozantinib mixture at step (a),c) stirring the reaction solution at step (b) at a suitable temperature,d) filtering to isolate the obtained solid,e) washing the obtained solid as pure crystalline cabozantinib hemifumarate sesquihydrate (Form A) or crystalline of cabozantinib hemifumarate hemipentahydrate (Form B) designated as Form A with a suitable solvent.
5. A pharmaceutical composition comprising crystalline Form A of cabozantinib hemifumarate sesquihydrate or crystalline Form B of cabozantinib hemifumarate hemipentahydrate and optionally at least one pharmaceutically acceptable excipient.
6. A medicament for the treatment of cancer comprising administering a therapeutically effective amount of crystalline Form A of cabozantinib hemifumarate sesquihydrate or crystalline Form B of cabozantinib hemifumarate hemipentahydrate.
7. A method of treating cancer comprising administering a therapeutically effective amount of crystalline Form A of cabozantinib hemifumarate sesquihydrate, wherein the crystalline Form A of cabozantinib hemifumarate sesquihydrate is characterized by an XPRD pattern having 2-theta values as shown in Figure 1.
8. A method of treating cancer comprising administering a therapeutically effective amount of crystalline Form B of cabozantinib hemifumarate hemipentahydrate, wherein the crystalline Form B of cabozantinib hemifumarate hemipentahydrate is characterized by an XPRD pattern having 2-theta values as shown in Figure 5.
9. The use of crystalline Form A of cabozantinib hemifumarate sesquihydrate or crystalline Form B of cabozantinib hemifumarate hemipentahydrate according to any one of the claims 1 to 9 in the manufacture of a medicament for the treatment of cancer disease.